[Federal Register Volume 65, Number 192 (Tuesday, October 3, 2000)]
[Notices]
[Pages 59005-59006]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-25284]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Cardiovascular and Renal Drugs Advisory Committee; Notice of 
Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

[[Page 59006]]

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed.
    Name of Committee: Cardiovascular and Renal Drugs Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on October 19, 2000, 
from 9 a.m. to 5 p.m., and on October 20, 2000, from 8:30 a.m. to 4 
p.m.
    Location: National Institutes of Health, 9000 Rockville Pike, 
Bldg. 10, Clinical Center, Jack Masur Auditorium, Bethesda, MD.
    Contact Person: Joan C. Standaert, Center for Drug Evaluation 
and Research (HFD-110), Food and Drug Administration, Woodmont II 
Bldg., 1451 Rockville Pike, Rockville, MD 20752, 419-259-6211, or 
John M. Treacy, 301-827-7001, or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 
12533. Please call the Information Line for up-to-date information 
on this meeting.
    Agenda: On October 19, 2000, the committee will meet in closed 
session. On October 20, 2000, the committee will discuss dose 
response using data from approved antihypertensive drugs.
    Procedure: On October 20, 2000, from 8:30 a.m. to 4 p.m., the 
meeting will be open to the public. Interested persons may present 
data, information, or views, orally or in writing, on issues pending 
before the committee. Written submissions may be made to the contact 
person by October 12, 2000. Oral presentations from the public will 
be scheduled between approximately 8:30 a.m. to 9:30 a.m. on October 
20, 2000. Time allotted for each presentation may be limited. Those 
desiring to make formal oral presentations should notify the contact 
person before October 12, 2000, and submit a brief statement of the 
general nature of the evidence or arguments they wish to present, 
the names and addresses of proposed participants, and an indication 
of the approximate time requested to make their presentation.
    Closed Committee Deliberations: On October 19, 2000, from 9 a.m. 
to 5 p.m., the meeting will be closed to permit discussion and 
review of trade secret and/or confidential information regarding 
pending investigational new drug applications and new drug 
applications (5 U.S.C. 552b(c)(4)).
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: September 22, 2000.
Bernard A. Schwetz,
Acting Deputy Commissioner.
[FR Doc. 00-25284 Filed 10-2-00; 8:45 am]
BILLING CODE 4160-01-F